Spots Global Cancer Trial Database for SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC
Official Title: An Open-label, Multicenter, Phase II Single Arm Trial of SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC
Study ID: NCT04106180
Conditions
Study Description
Brief Summary: This study is an open-label, multicenter, phase II single arm trial to evaluate the efficacy and safety of SBRT in combination with sintilimab and GM-CSF for the treatment of patients with advanced NSCLC.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Fudan University Shanghai Cancer Center, Shanghai, , China
Contact Details
Name: Zhengfei Zhu, MD
Affiliation: Fudan University
Role: PRINCIPAL_INVESTIGATOR
Name: Xinghao Ai
Affiliation: Shanghai Chest Hospital
Role: STUDY_DIRECTOR
Name: Zhengbo Han
Affiliation: Shengjing Hospital
Role: STUDY_DIRECTOR
Name: Qian Chu
Affiliation: Tongji Hospital
Role: STUDY_DIRECTOR
Name: Xiaorong Dong
Affiliation: Union Hospital
Role: STUDY_DIRECTOR
Name: Lin Wu
Affiliation: Hunan Cancer Hospital
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
